Published in Medical Letter on the CDC and FDA, November 21st, 2004
And since chicken flocks for next year's vaccine are already established and plants already run at full capacity, it's unclear how much Aventis Pasteur or any single company can goose up production to cover a shortfall like this year's loss of Chiron Corp.'s vaccine.
As Chiron executive Dr. Kevin Bryett said in an interview 2 weeks before its British factory was shut down: "If the market was to change dramatically, it is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.